Newsy's Latest Health News

AstraZeneca reports its COVID-19 vaccine is up to 90% effective, with plans to apply for emergency use authorization. The vaccine's efficacy varies between 70% and 90% based on dosing. AstraZeneca aims to produce 200 million doses by year-end and up to 3 billion next year. The FDA has authorized Regeneron's antibody cocktail for treating mild to moderate COVID-19 in high-risk patients. Initial doses will be available to 300,000 patients by January 2021. Special thanks to Kaiser Health News for their collaboration.

What is the reported effectiveness range of AstraZeneca's experimental coronavirus vaccine?

• 80% to 100%

• 50% to 60%

• 60% to 70%

• 70% to 90%

What is the purpose of Regeneron's coronavirus antibody cocktail?

• To cure severe COVID-19 cases

• To treat mild to moderate COVID-19 patients at higher risk

• To replace vaccines

• To prevent COVID-19 in healthy individuals

Who are considered at higher risk for severe illness from COVID-19 according to the FDA?

• Athletes

• Individuals over 65 or with chronic conditions

• Children under 12

• People with no underlying conditions

By when does Regeneron plan to make initial doses of its antibody cocktail available?

• End of December 2020

• End of January 2021

• End of February 2021

• End of March 2021

How many patients does Regeneron aim to treat with its initial doses by January 2021?

• 400,000 patients

• 300,000 patients

• 200,000 patients

• 100,000 patients